169 related articles for article (PubMed ID: 15265901)
1. MUC1/sec-expressing tumors are rejected in vivo by a T cell-dependent mechanism and secrete high levels of CCL2.
Grosso JF; Herbert LM; Owen JL; Lopez DM
J Immunol; 2004 Aug; 173(3):1721-30. PubMed ID: 15265901
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of Mucin 1/sec involves the modulation of urokinase-type plasminogen activator and signal transducer and activator of transcription 1 expression in tumor cells.
Ilkovitch D; Handel-Fernandez ME; Herbert LM; Lopez DM
Cancer Res; 2008 Apr; 68(7):2427-35. PubMed ID: 18381451
[TBL] [Abstract][Full Text] [Related]
3. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice.
Di Carlo E; Comes A; Orengo AM; Rosso O; Meazza R; Musiani P; Colombo MP; Ferrini S
J Immunol; 2004 Feb; 172(3):1540-7. PubMed ID: 14734732
[TBL] [Abstract][Full Text] [Related]
4. MUC1-specific anti-tumor responses: molecular requirements for CD4-mediated responses.
VanLith ML; Kohlgraf KG; Sivinski CL; Tempero RM; Hollingsworth MA
Int Immunol; 2002 Aug; 14(8):873-82. PubMed ID: 12147624
[TBL] [Abstract][Full Text] [Related]
5. A unique mucin immunoenhancing peptide with antitumor properties.
Herbert LM; Grosso JF; Dorsey M; Fu T; Keydar I; Cejas MA; Wreschner DH; Smorodinski N; Lopez DM
Cancer Res; 2004 Nov; 64(21):8077-84. PubMed ID: 15520219
[TBL] [Abstract][Full Text] [Related]
6. Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines.
Sivinski CL; Kohlgraf KG; VanLith ML; Morikane K; Tempero RM; Hollingsworth MA
Cancer Immunol Immunother; 2002 Aug; 51(6):327-40. PubMed ID: 12111121
[TBL] [Abstract][Full Text] [Related]
7. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity.
Bannerji R; Arroyo CD; Cordon-Cardo C; Gilboa E
J Immunol; 1994 Mar; 152(5):2324-32. PubMed ID: 7907636
[TBL] [Abstract][Full Text] [Related]
8. Two distinct populations of primary cytotoxic cells infiltrating into allografted tumor rejection sites: infiltration of macrophages cytotoxic against allografted tumor precedes that of multiple sets of cytotoxic T lymphocytes with distinct specificity to alloantigens.
Yoshida R; Matsuura A; Einaga K; Ushio Y; Yamamoto N; Yoneda Y
Microbiol Immunol; 1997; 41(2):149-59. PubMed ID: 9087957
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of antitumor and immune-enhancing activities of MUC1/sec, a secreted form of mucin-1.
Ilkovitch D; Carrio R; Lopez DM
Immunol Res; 2013 Dec; 57(1-3):70-80. PubMed ID: 24222275
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-mediated recruitment of myeloid-derived suppressor cells and their suppressive mechanisms are blocked by MUC1/sec.
Ilkovitch D; Lopez DM
Blood; 2009 May; 113(19):4729-39. PubMed ID: 19196663
[TBL] [Abstract][Full Text] [Related]
11. MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells.
Wright SE; Rewers-Felkins KA; Quinlin IS; Fogler WE; Phillips CA; Townsend M; Robinson W; Philip R
Immunol Invest; 2008; 37(3):215-25. PubMed ID: 18389441
[TBL] [Abstract][Full Text] [Related]
12. IL-12 administered in vivo to young and aged mice. Discrepancy between the effects on tumor growth in vivo and cytotoxic T lymphocyte generation ex vivo: dependence on IFN-gamma.
Horvath-Arcidiacono JA; Mostowski HS; Bloom ET
Int Immunol; 1996 May; 8(5):661-73. PubMed ID: 8671653
[TBL] [Abstract][Full Text] [Related]
13. Impact of tumor-derived CCL2 on T cell effector function.
Vitiello PF; Shainheit MG; Allison EM; Adler EP; Kurt RA
Immunol Lett; 2004 Feb; 91(2-3):239-45. PubMed ID: 15019295
[TBL] [Abstract][Full Text] [Related]
14. CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice.
Tempero RM; VanLith ML; Morikane K; Rowse GJ; Gendler SJ; Hollingsworth MA
J Immunol; 1998 Nov; 161(10):5500-6. PubMed ID: 9820526
[TBL] [Abstract][Full Text] [Related]
15. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
16. Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens.
Apostolopoulos V; Xing PX; McKenzie IF
Cancer Res; 1994 Oct; 54(19):5186-93. PubMed ID: 7923138
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution.
Alajez NM; Schmielau J; Alter MD; Cascio M; Finn OJ
Blood; 2005 Jun; 105(12):4583-9. PubMed ID: 15746083
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.
Hillman GG; Reich LA; Rothstein SE; Abernathy LM; Fountain MD; Hankerd K; Yunker CK; Rakowski JT; Quemeneur E; Slos P
J Immunother Cancer; 2017; 5():4. PubMed ID: 28116088
[TBL] [Abstract][Full Text] [Related]
19. Cross-talk between T cells and innate immune cells is crucial for IFN-gamma-dependent tumor rejection.
Li Z; Pradera F; Kammertoens T; Li B; Liu S; Qin Z
J Immunol; 2007 Aug; 179(3):1568-76. PubMed ID: 17641023
[TBL] [Abstract][Full Text] [Related]
20. The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement.
Di Carlo E; Comes A; Basso S; De Ambrosis A; Meazza R; Musiani P; Moelling K; Albini A; Ferrini S
J Immunol; 2000 Sep; 165(6):3111-8. PubMed ID: 10975824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
